Trial reportPediatric research2026
Anti-inflammatory effects of Bifidobacterium infantis M-63 during the early postnatal period in term infants.
Trial report in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Saffron Alters Microbial Amino Acid Metabolism and Neurotransmitter Production in a Defined Gut Consortium.Food science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe administration of Bifidobacterium infantis M-63 during the early postnatal period enhances the abundance of gut Bifidobacterium, but its potential effects are still unexplored. The present study aimed to evaluate the impact of B. infantis M-63 on immunity, inflammation, gut-derived metabolites, and gut microbiota composition-based enterotypes in healthy infants.
methodsFecal samples were collected from 111 healthy infants randomly administered 1.0 × 10
resultsAdministering Bifidobacterium infantis M-63 significantly increased gut Bifidobacterium, whereas Enterobacteriaceae abundance and proinflammatory cytokine levels decreased. Six enterotypes were identified among the gut microbiota. In Bifidobacterium-dominant enterotypes, there was a significant increase in acetic acid and tryptophan metabolite levels, and a slight increase in sIgA levels. In contrast, levels of calprotectin and inflammatory cytokines were significantly reduced compared to those in the non-Bifidobacterium enterotypes.
conclusionsBifidobacterium-dominant enterotypes, established in the gut after administration of B. infantis M-63, were strongly associated with anti-inflammatory effects in healthy infants. IMPACT: This is the first study to demonstrate an anti-inflammatory effect in healthy full-term infants supplemented with Bifidobacterium infantis M-63 alone. Bifidobacterium-dominant enterotypes were associated with reduced levels of inflammatory cytokines and calprotectin, and increased production of beneficial tryptophan metabolites, such as Indole-3-lactic acid (ILA). This study provides evidence that supplementation with B. infantis M-63 in infants may significantly reduce inflammation during the critical early postnatal period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.